Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China SXT PharmaceuticalsFRA:2RY2 -2.38%19 EV-to-OCF is 6.35 as of Aug. 13, 2026, which is 12% below its 10-year median of 7.18. GuruFocus rates FRA:2RY2 with a GF Score™ of 19/100 and a GF Value™ of €5.74 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 1,006 Drug Manufacturers companies, China SXT Pharmaceuticals ranks better than 60.93% on this metric.
The historical rank and industry rank for China SXT Pharmaceuticals's EV-to-OCF or its related term are showing as below:
FRA:2RY2'
s EV-to-OCF Range Over the Past 10 Years
Min: -1.61 Med: 7.18 Max: 7.25
Current: 6.27
During the past 10 years, the highest EV-to-OCF of China SXT Pharmaceuticals was 7.25. The lowest was -1.61. And the median was 7.18.
FRA:2RY2's EV-to-OCF is ranked better than 60.93% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.145
vs FRA:2RY2: 6.27
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China SXT Pharmaceuticals (FRA:2RY2) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China SXT Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
China SXT Pharmaceuticals's share price for today is €3.037.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China SXT Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-7.668.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
China SXT Pharmaceuticals EV-to-OCF Related Terms
China SXT Pharmaceuticals EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's EV-to-OCF falls into.
China SXT Pharmaceuticals's current Enterprise Value is €-21.91 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China SXT Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was €-3.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China SXT Pharmaceuticals (FRA:2RY2) has a EV-to-OCF of 6.35 as of Aug. 13, 2026. This is 12% below median its historical median of 7.18. According to the industry distribution chart, China SXT Pharmaceuticals ranks #393 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 39.1%.
Is China SXT Pharmaceuticals' EV-to-OCF too high?
China SXT Pharmaceuticals' current EV-to-OCF of 6.35 is 12% below median its 10-year median of 7.18. The Drug Manufacturers industry median EV-to-OCF is 11.15. China SXT Pharmaceuticals' value of 6.35 is 43% below this industry median. Based on the distribution chart, China SXT Pharmaceuticals ranks #393 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China SXT Pharmaceuticals has a GF Score™ of 19/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' EV-to-OCF compare to CBIH and UPC?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #393 out of 1006 companies for EV-to-OCF. This puts China SXT Pharmaceuticals in the upper half of its industry. The industry median EV-to-OCF is 11.15. China SXT Pharmaceuticals' value of 6.35 is 43% below this benchmark. While the company's 10-year median is 7.18 vs. the industry median of 11.15, China SXT Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.15, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China SXT Pharmaceuticals's current EV-to-OCF of 6.35 is 43% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current EV-to-OCF is 6.35, which is 12% below median its own 10-year median of 7.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, China SXT Pharmaceuticals (FRA:2RY2) is currently considered Possible Value Trap. The stock's GF Value™ is €5.74, compared to a current price of €3.04 — trading 47.1% below its estimated fair value. The current EV-to-OCF is 6.35, which is 12% below median its 10-year median of 7.18 and 43% below the Drug Manufacturers industry median of 11.15. China SXT Pharmaceuticals' overall GF Score™ is 19/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For China SXT Pharmaceuticals (FRA:2RY2), the current EV-to-OCF is 6.35 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China SXT Pharmaceuticals (FRA:2RY2) Overvalued in 2026?
Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be undervalued.
The current stock price of €3.04 is trading 47.1% below its estimated GF Value™ of €5.74.
GuruFocus considers China SXT Pharmaceuticals to be Possible Value Trap.
Key valuation signals for FRA:2RY2:
EV-to-OCF: 6.35 (12% below median its 10-year median of 7.18)
GF Value™: €5.74 vs. price of €3.04 (47.1% below fair value)
Industry Position: 43% below the Drug Manufacturers median (#393 of 1006)
No single metric tells the full story. See the FRA:2RY2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
19GF Score
Get the complete analysis for FRA:2RY2
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2RY2 has been successfully added to your 
